(Q38394272)

2 September 2017

1 reference

title

Biosimilar monoclonal antibodies in lymphoma: a critical appraisal (English)

1 reference

2 September 2017

1 reference

1

Catherine Rioufol

0 references

author name string

Catherine Rioufol

series ordinal

1

1 reference

2 September 2017

Gilles Salles

series ordinal

2

1 reference

2 September 2017

publication date

30 March 2015

1 reference

Expert Review of Anticancer Therapy

2 September 2017

published in

1 reference

2 September 2017

volume

15

1 reference

2 September 2017

issue

5

1 reference

2 September 2017

page(s)

569-578

1 reference

Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

A unique cell surface antigen identifying lymphoid malignancies of B cell origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Mechanisms of killing by anti-CD20 monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Monoclonal antibodies in cancer therapy: 25 years of progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Anti-CD20 monoclonal antibodies: historical and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Update on obinutuzumab in the treatment of B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

A pilot study of rituximab in patients with recurrent, classic Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Next generation and biosimilar monoclonal antibodies: essential considerations towards regulatory acceptance in Europe. February 3-4, 2011, Freiburg, Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Diffuse large B-cell lymphoma in the elderly: a review of potential difficulties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Endpoints for assessing drug activity in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Rituximab dose-escalation trial in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Evolution of anti-CD20 monoclonal antibody therapeutics in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Mouse model recapitulating human Fcγ receptor structural and functional diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

The future of anti-CD20 monoclonal antibodies: are we making progress?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Interindividual variability of response to rituximab: from biological origins to individualized therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Anti-CD20 antibody therapy for B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Are we nearing an era of chemotherapy-free management of indolent lymphoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1028919

10.1586/14737140.2015.1028919

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference